会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • TRANSORAL DOSAGE FORMS COMPRISING SUFENTANIL AND NALOXONE
    • 包含SUFENTANIL和NALOXONE的转运剂型
    • US20100010031A1
    • 2010-01-14
    • US12449292
    • 2008-02-08
    • Su Yum, IIJaymin ShahSung Yun KwonXiaoping Song
    • Su Yum, IIJaymin ShahSung Yun KwonXiaoping Song
    • A61K31/4535A61K31/485
    • A61K31/4535A61K9/0056A61K9/006A61K9/06A61K9/2009A61K9/2063A61K9/7007A61K31/485A61K2300/00
    • The invention pertains to methods that include administering to a subject a transoral dosage form comprising a pharmaceutical carrier and sufentanil, and maintaining a mean pH ranging from about 3.5 to about 5.5 during a dosing period after administration of the transoral dosage form as determined using an in vitro donor media test. Related dosage forms are also disclosed. Also disclosed are transoral dosage forms and related methods, wherein a transoral dosage form may comprise: (1) about 5 to about 1000 micrograms of sufentanil; (2) about 50 micrograms to about 100 milligrams of naloxone; and (3) acidifying material in an amount sufficient to provide a mean pH ranging from about 3.5 to about 5.5 during a dosing period after administration of the transoral dosage form as determined using an in vitro donor media test; wherein the dosing period begins no earlier than about 1 minute after administration of the transoral dosage form, and ends no later than about 120 minutes after administration of the transoral dosage form.
    • 本发明涉及包括向受试者施用包含药物载体和舒芬太尼的经口给药形式的方法,并且在给予经口给药后的给药期间保持约3.5至约5.5的平均pH,所述给药期间使用 体外供体介质试验。 还公开了相关的剂型。 还公开了经口给药剂型和相关方法,其中经口剂型可包含:(1)约5至约1000微克的舒芬太尼; (2)约50微克至约100毫克的纳洛酮; 和(3)足量的酸化材料,其在施用经口给药形式后的给药期间提供约3.5至约5.5的平均pH,使用体外供体培养基测试确定; 其中给药期在给予经口给药后不早于约1分钟开始,并且在给予经口给药后不迟于约120分钟结束。
    • 5. 发明申请
    • Parenteral and oral formulations of benzimidazoles
    • 苯并咪唑的肠胃外和口服制剂
    • US20080293796A1
    • 2008-11-27
    • US12220364
    • 2008-07-24
    • Diana Shu-Lian ChowPranav GuptaYulan QiJaymin ShahPeter Wisniecki
    • Diana Shu-Lian ChowPranav GuptaYulan QiJaymin ShahPeter Wisniecki
    • A61K31/4184A61P35/00
    • A61K9/0019A61K9/0095A61K9/1075A61K31/4184
    • Provided herein are drug delivery systems comprising nanosuspension formulations suitable for parenteral delivery to a subject. The nanosuspension formulations may comprise a benzimidazole derivative, e.g., mebendazole, and surface stabilizers, such as block copolymer(s), e.g., Pluronic F108, and surfactant(s), e.g., Tween 80, and, optionally, water. Provided are methods for defining nanosuspensions of a benzimidazole derivative as having maximum therapeutic efficacy for a treatment regimen by adjusting and/or selecting particles size(s) based on pharmacokinetic parameters of the derivative in the tissue. Also provided are methods for improving the bioavailability of a benzimidazole derivative during treatment of a pathophysiological condition and for treating a cancer by using formulation(s) combining particle diameters whereby the retention of the benzimidazole derivative within the particles increases as the diameter increases such that, upon administration, release of the benzimidazole derivative from the particles into tissue is continuous over a range of time as determined by the particle diameters.
    • 本文提供的药物递送系统包括适于肠胃外递送给个体的纳米悬浮制剂。 纳米悬浮液制剂可以包含苯并咪唑衍生物,例如甲苯咪唑和表面稳定剂,例如嵌段共聚物,例如Pluronic F108和表面活性剂,例如吐温80和任选的水。 提供了通过基于组织中衍生物的药代动力学参数调节和/或选择颗粒大小来定义苯并咪唑衍生物的纳米悬浮液对于治疗方案具有最大治疗功效的方法。 还提供了用于在治疗病理生理状况期间改善苯并咪唑衍生物的生物利用度和通过使用结合粒径的配方治疗癌症的方法,由此直径增加时,颗粒内苯并咪唑衍生物的保留增加, 在施用时,将苯并咪唑衍生物从颗粒中释放到组织中在由颗粒直径确定的时间范围内是连续的。